PMID- 36806191
OWN - NLM
STAT- MEDLINE
DCOM- 20230811
LR  - 20230811
IS  - 1470-8744 (Electronic)
IS  - 0885-4513 (Linking)
VI  - 70
IP  - 4
DP  - 2023 Aug
TI  - Banxia Xiexin decoction ameliorates dextran sulfate sodium (DSS)-induced 
      ulcerative colitis via inhibiting serine-threonine protein kinase 
      (Akt)/mitogen-activated protein kinase (MAPK) signaling pathway.
PG  - 1530-1542
LID - 10.1002/bab.2451 [doi]
AB  - Banxia Xiexin decoction (BXD), a traditional Chinese medicine, was widely used in 
      treating ulcerative colitis (UC). However, the active components of BXD and its 
      mechanism in UC remain elusive. Therefore, we used network pharmacology in vivo 
      experiments, molecular docking, and surface plasmon resonance strategy (SPR) to 
      uncover BXD's potential mechanism. A UC rat model was established by orally 
      administering 7% dextran sulfate sodium (DSS) in drinking water, BXD and 
      palmatine were orally administered for 7 days. Network pharmacology was used to 
      investigate the main bioactive components and crucial targets of BXD in treating 
      UC. Molecular docking was used to investigate interactions between components and 
      crucial targets, verifying the results by SPR. By network pharmacology 
      predicting, 20 active components and 44 candidate anti-UC targets of BXD were 
      identified, and the crucial proteins were screeded from PPI network, including 
      extracellular regulated protein kinases (ERK), AKT1, and tumor necrosis factor-alpha 
      (TNF). In addition, some key active components (palmatine, sexangularetin, and 
      skullcapflavone II) were screened out from the active components-targets network. 
      Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment and in vivo experiments 
      showed that protein-serine-threonine kinase (Akt)/MAPK pathway was involved in 
      BXD treatment for UC; BXD and palmatine significantly ameliorated the severity of 
      DSS-induced UC in rats. Our study might assist in further investigation of the 
      active components in Chinese medicine.
CI  - (c) 2023 International Union of Biochemistry and Molecular Biology, Inc.
FAU - Ji, Wanli
AU  - Ji W
AD  - School of Pharmacy, Shanghai University of Medicine and Health Sciences, 
      Shanghai, China.
FAU - Liu, Wangzhenzu
AU  - Liu W
AD  - School of Pharmacy, Shanghai University of Traditional Chinese Medicine, 
      Shanghai, China.
FAU - Huo, Yan
AU  - Huo Y
AD  - Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai 
      University of Traditional Chinese Medicine, Shanghai, China.
FAU - Hu, Cheng
AU  - Hu C
AD  - Science and Technology Experiment Center, Shanghai University of Traditional 
      Chinese Medicine, Shanghai, China.
FAU - Zhang, Yifan
AU  - Zhang Y
AUID- ORCID: 0000-0002-7946-1808
AD  - School of Pharmacy, Shanghai University of Medicine and Health Sciences, 
      Shanghai, China.
LA  - eng
GR  - 82204741/National Natural Science Foundation of China/
GR  - SSF-21-07-002/Scientific Research Foundation of Shanghai University of Medicine 
      and Health Sciences/
PT  - Journal Article
DEP - 20230320
PL  - United States
TA  - Biotechnol Appl Biochem
JT  - Biotechnology and applied biochemistry
JID - 8609465
RN  - EC 2.7.11.24 (Mitogen-Activated Protein Kinases)
RN  - 0 (banxia xiexin decoction)
RN  - 9042-14-2 (Dextran Sulfate)
RN  - EC 2.7.11.1 (Proto-Oncogene Proteins c-akt)
RN  - EC 2.7.11.1 (Protein Serine-Threonine Kinases)
RN  - 0 (Drugs, Chinese Herbal)
SB  - IM
MH  - Animals
MH  - Rats
MH  - Mitogen-Activated Protein Kinases
MH  - Dextran Sulfate/toxicity
MH  - Proto-Oncogene Proteins c-akt
MH  - *Colitis, Ulcerative/chemically induced/drug therapy
MH  - Molecular Docking Simulation
MH  - Signal Transduction
MH  - Protein Serine-Threonine Kinases
MH  - *Drugs, Chinese Herbal/pharmacology
OTO - NOTNLM
OT  - Akt
OT  - Banxia Xiexin decoction
OT  - MAPK
OT  - inflammatory bowel disease
OT  - ulcerative colitis
EDAT- 2023/02/23 06:00
MHDA- 2023/08/11 06:43
CRDT- 2023/02/22 10:27
PHST- 2022/10/10 00:00 [received]
PHST- 2023/02/11 00:00 [accepted]
PHST- 2023/08/11 06:43 [medline]
PHST- 2023/02/23 06:00 [pubmed]
PHST- 2023/02/22 10:27 [entrez]
AID - 10.1002/bab.2451 [doi]
PST - ppublish
SO  - Biotechnol Appl Biochem. 2023 Aug;70(4):1530-1542. doi: 10.1002/bab.2451. Epub 
      2023 Mar 20.